Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Biome Australia Limited (BIO.AX)
Cremorne, VIC, AU
Biome Australia Limited, founded in 2018 and headquartered in Cremorne, Australia, specializes in the development, commercialization, and global distribution of live biotherapeutic and complementary health products. The company's product line features live biotherapeutics under the Activated Probiotics brand, organic nutritional supplements branded as Activated Nutrients, and athletic performance and recovery items named Activated X Performance. These offerings are accessible to consumers through both community pharmacies and independent health practitioners.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.13% | -10.58% | -21.19% | -44.64% | -47.16% | -44.64% | -49.46% | +218.49% | +93.75% | +93.75% | +93.75% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+41.6% ★ Q4'25: +106.1% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+112.5% ★ Q4'25: +169.3% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-27.6% Q4'25: +16.5% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+0.0% Q4'25: +5.5% (vs Q4'23)
-
ROIC Biotechnology: -16.1%0.0% ★ Q4'25: +52.8% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+5.0% Q4'25: +11.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×21.41× Q4'25: 0.74× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
Jun 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
4.11M
est: 4.12M (-0.2%)
|
7.24M
est: 7.23M (+0.1%)
|
13.01M
est: 12.70M (+2.4%)
|
18.42M
est: 18.40M (+0.1%)
|
25.60M
25.60M – 25.60M
+39.1% YoY
|
36.40M
36.40M – 36.40M
+42.2% YoY
|
50.20M
50.20M – 50.20M
+37.9% YoY
|
| EBITDA |
-4.65M
est: -2.10M (-121.1%)
|
-3.15M
est: -3.69M (+14.4%)
|
-1.58M
est: -6.48M (+75.6%)
|
143.6K
est: -9.38M (+101.5%)
|
-13.05M
-13.05M – -13.05M
-39.1% YoY
|
-18.56M
-18.56M – -18.56M
-42.2% YoY
|
-25.60M
-25.60M – -25.60M
-37.9% YoY
|
| EBIT |
-4.73M
est: -2.15M (-120.2%)
|
-3.37M
est: -3.77M (+10.4%)
|
-1.82M
est: -6.62M (+72.5%)
|
-361.00
est: -9.59M (+100.0%)
|
-13.34M
-13.34M – -13.34M
-39.1% YoY
|
-18.97M
-18.97M – -18.97M
-42.2% YoY
|
-26.17M
-26.17M – -26.17M
-37.9% YoY
|
| Net Income |
-4.54M
est: -5.46M (+16.9%)
|
-3.08M
est: -3.06M (-0.7%)
|
-1.67M
est: -2.40M (+30.5%)
|
214.7K
est: 218.5K (-1.7%)
|
3.28M
3.28M – 3.28M
+1,400.0% YoY
|
7.21M
7.21M – 7.21M
+120.0% YoY
|
9.18M
9.18M – 9.18M
+27.3% YoY
|
| SGA |
5.84M
est: 5.45M (+7.1%)
|
7.33M
est: 9.56M (-23.3%)
|
9.58M
est: 16.79M (-42.9%)
|
10.98M
est: 24.33M (-54.9%)
|
33.84M
33.84M – 33.84M
+39.1% YoY
|
48.12M
48.12M – 48.12M
+42.2% YoY
|
66.37M
66.37M – 66.37M
+37.9% YoY
|
| EPS |
-0.02
est: -0.03 (+9.2%)
|
-0.02
est: -0.01 (-9.3%)
|
-0.01
est: -0.01 (+27.3%)
|
0.00
est: 0.00 (+0.0%)
|
0.02
0.02 – 0.02
+1,400.0% YoY
|
0.03
0.03 – 0.03
+120.0% YoY
|
0.04
0.04 – 0.04
+27.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-28 | B | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-27 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-26 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-25 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | B | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | B | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | B | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | B | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-01 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Blair William Brabin Vega Norfolk | MD, Chief Executive Officer & Director | 580.0K | male |
| Lauren Dwyer | Chief Financial Officer | 430.0K | female |
| Jaroslav Haman Boublik | Chief Science Officer & Member of Scientific Advisory Board | 344.8K | — |
| George Lazarou | Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BIO.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
